Geodon Side Effects
Generic Name: ziprasidone
Note: This document contains side effect information about ziprasidone. Some of the dosage forms listed on this page may not apply to the brand name Geodon.
Some side effects of Geodon may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to ziprasidone: oral capsule
Other dosage forms:
Along with its needed effects, ziprasidone (the active ingredient contained in Geodon) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking ziprasidone:More common
- difficulty with speaking
- fear or nervousness
- inability to sit still
- loss of balance control
- muscle trembling, jerking, or stiffness
- need to keep moving
- shuffling walk
- sore throat
- stiffness of the limbs
- twisting movements of the body
- uncontrolled movements, especially of the face, neck, and back
- Blurred vision
- body aches or pain
- chest pain
- fast, pounding, or irregular heartbeat or pulse
- pounding in the ears
- runny nose
- slow or fast heartbeat
- swelling of the tongue
- tender, swollen glands in the neck
- trouble with swallowing
- voice changes
- Fainting or feeling faint
- feeling faint upon standing
- persistent, painful erection
- Inability to move the eyes
- increased blinking or spasms of the eyelid
- sticking out of tongue
- trouble with breathing, speaking, or swallowing
- uncontrolled twisting movements of the neck, trunk, arms, or legs
- unusual facial expressions
Get emergency help immediately if any of the following symptoms of overdose occur while taking ziprasidone:Symptoms of overdose
- shakiness in the legs, arms, hands, or feet
- slurred speech
- trembling or shaking of the hands or feet
Some side effects of ziprasidone may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- Acid or sour stomach
- lack or loss of strength
- stomach discomfort, upset, or pain
- weight gain
- Blistering, crusting, irritation, itching, or reddening of the skin
- burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
- change in vision
- cracked, dry, or scaly skin
- difficulty with moving
- dry mouth
- increase in salivation
- itching or reddening of the skin
- joint pain
- loss of appetite
- muscle ache
- muscle pains or stiffness
- muscle tightness
- stuffy nose
- swollen joints
- weakness of the arms and legs
- weight loss
For Healthcare Professionals
Applies to ziprasidone: intramuscular powder for injection, oral capsule
Nervous system side effects have frequently included extrapyramidal symptoms encompassing hypertonia, dystonia, dyskinesia, hypokinesia, tremor, paralysis, and twitching. Extrapyramidal side effects have been reported in 14% and 31% of patients with schizophrenia and bipolar mania, respectively, though no one effect occurred individually at an incidence greater than 10% in the bipolar mania trials. Headache (18%), somnolence (14% to 31%), dizziness/lightheadedness (8% to 16%), akathisia (8% to 10%), anxiety (5%), asthenia (5%), insomnia (3%), hypesthesia (2%), speech disorder (2%), agitation, hostility, paresthesia, confusion, vertigo, hyperkinesia, abnormal gait, oculogyric crisis, hypesthesia, ataxia, amnesia, cogwheel rigidity, delirium, hypotonia, akinesia, dysarthria, withdrawal syndrome, buccoglossal syndrome, choreoathetosis, diplopia, incoordination, and neuropathy have also been reported frequently. Paralysis has been reported infrequently. Myoclonus, nystagmus, torticollis, circumoral paresthesia, opisthotonos, increased reflexes, neuromalignant syndrome, and trismus have been reported rarely. Single cases of tardive dystonia and parkinsonism have been reported. Syncope, serotonin syndrome (alone or in combination with other serotonergic agents), and facial droop have been observed in postmarketing use.
Ziprasidone (the active ingredient contained in Geodon) has been associated with improvement on cognitive test performance in patients in the early stages of schizophrenia.
A 20-year-old male with a history of auditory hallucinations, paranoid delusions, flat affect, and social withdrawal, showed signs of mania following 7 days of ziprasidone therapy at a final dose of 80 mg once at bedtime. Symptoms resolved approximately 48 hours following discontinuation of ziprasidone therapy.
A 53-year-old male diagnosed with schizoaffective disorder at 12 years of age was admitted from the emergency room with a diagnosis of schizophrenia, paranoid type. The patient denied receiving pharmacological treatment in the previous 3 month time period. Ziprasidone therapy was initiated with 40 mg orally twice a day on Day 1 followed by a dosage adjustment to 80 mg twice a day on Day 2. The patient demonstrated notable torticollis and dystonic posturing of his left carpus approximately four hours following his sixth 80 mg dose. Palpitation of his musculature revealed spasm. The patient had normal lab values and was deemed to be without general medical conditions. Muscular contraction was relieved with injectable diphenhydramine. Ziprasidone was discontinued and the patient showed no signs of recurrence during a subsequent 24-hour observation period. Soon thereafter the patient left the facility against medical advice and without further pharmacologic treatment. The rapid increase in dosage may have contributed to the observed dystonia.
A 12-year-old male with a history of schizoaffective disorder was switched from risperidone orally 2 mg once a day (because of facial twitching) to ziprasidone orally 80 mg once a day. Approximately 8-weeks after initiation of ziprasidone therapy the patient presented to the emergency room as rigid, diaphoretic, tremulous, difficult to arouse, and with tactile fever, urinary incontinence, and incoherent speech. Ziprasidone was discontinued and the patient was treated for neuroleptic malignant syndrome (NMS). The patient was assessed approximately 2 months after the incident and was deemed to have made a full neurologic and physical recovery.
Five female patients with bipolar disorder receiving ziprasidone (80 to 160 mg/day) developed severe and abrupt akathisia following a dose reduction. In each case, akathisia resolved following treatment and/or discontinuation of ziprasidone.
Lower (worse) baseline scores predicted greater cognitive improvement. Change In cognitive performance was weakly related to change in symptom scores.
Gastrointestinal side effects have frequently included nausea (10%), constipation (9%), dyspepsia (8%), diarrhea (5%), vomiting (5%), increased salivation (4%), dry mouth (4%), tongue edema (3%), dysphagia (2%), anorexia (2%), tooth disorder, abdominal pain, and dry mouth. Rectal hemorrhage has been reported infrequently. Gum hemorrhage, fecal impaction, hematemesis, leukoplakia of mouth, melena, and swollen tongue have also been reported.
Collective data gathered from 17 placebo-controlled clinical studies (n=5106) involving the use of atypical antipsychotic agents for the treatment of behavioral disorders in the elderly patient with dementia showed a risk of death 1.6 to 1.7 times greater in the drug-treated patient than in the placebo-treated patient. The average length of duration for the trials was 10 weeks with the cause of death in the majority of cases, though not all, reported as either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Although ziprasidone (the active ingredient contained in Geodon) was not included in these studies, the consistent findings across all three relevant chemical classes support the opinion that these findings are likely to be applicable to all atypical antipsychotic agents. Ziprasidone is not approved by the FDA for use in the treatment of behavioral disorders in elderly patients with dementia.
Respiratory side effects have frequently included respiratory tract infections (8%), rhinitis (4%), increased cough (3%), pharyngitis (3%), and dyspnea (2%). Pneumonia and epistaxis have also been reported. Hemoptysis and laryngismus have been reported rarely.
Dermatologic side effects have frequently included rash (4%), fungal dermatitis (2%), furunculosis, and sweating. Maculopapular rash, urticaria, alopecia, eczema, exfoliative dermatitis, contact dermatitis, and vesiculobullous rash have also been reported.
The manufacturer reports the most common event associated with dropout in two short-term placebo-controlled studies involving patients receiving oral ziprasidone was rash (1%).
Ocular side effects have frequently included abnormal vision in up to 6% of patients. Conjunctivitis, dry eyes, blepharitis, cataract, and photophobia have also been reported. Eye hemorrhage, visual field defects, keratitis, and keratoconjunctivitis have been reported rarely.
In schizophrenia trials, oral ziprasidone (the active ingredient contained in Geodon) was associated with a mean increase in heart rate of 1.4 beats per minute compared to a 0.2 beats per minute decrease in placebo patients.
Collective data gathered from 17 placebo-controlled clinical studies (n=5106) involving the use of atypical antipsychotic agents for the treatment of behavioral disorders in the elderly patient with dementia showed a risk of death 1.6 to 1.7 times greater in the drug-treated patient than in the placebo-treated patient. The average length of duration for the trials was 10 weeks with the cause of death in the majority of cases, though not all, reported as either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Although ziprasidone was not included in these studies, the consistent findings across all three relevant chemical classes support the opinion that these findings are likely to be applicable to all atypical antipsychotic agents. Ziprasidone is not approved by the FDA for use in the treatment of behavioral disorders in elderly patients with dementia.
Cardiovascular side effects have frequently included tachycardia (2%), hypertension (3%), chest pain (3%), postural hypotension (1%), bradycardia, and vasodilation. Increase in QTc interval, angina pectoris, atrial fibrillation have also been reported. First degree AV block, bundle branch block, phlebitis, pulmonary embolus, cardiomegaly, cerebral infarct, cerebrovascular accident, deep thrombophlebitis, myocarditis, thrombophlebitis, and Torsade de Pointes have been reported rarely.
Endocrine side effects have included hyperprolactinemia, hyperglycemia, and diabetes mellitus. Hypothyroidism, hyperthyroidism, thyroiditis, hypoglycemia, decreased glucose tolerance, hypoglycemic reaction, and ketosis have been reported rarely. A significant reduction in serum cholesterol and triglycerides has been reported in one study (n=37).
Hyperprolactinemia in some patients may cause sexual dysfunction and menstrual irregularities. In addition, as many as one-third of human breast cancers may be prolactin-dependent in vitro.
Studies have demonstrated that patients receiving atypical antipsychotics (i.e., clozapine, risperidone, olanzapine, quetiapine, ziprasidone) are at an increased risk of developing hyperglycemia and/or diabetes mellitus.
Musculoskeletal side effects have included myalgia (2%) and tenosynovitis (less than 1%). Myopathy has been reported rarely.
A one year study reported clinically significant weight gain, as defined by an increase in body weight of greater than or equal to 7%, in 5% to 11% of ziprasidone (the active ingredient contained in Geodon) recipients. However, median weight actually decreased from baseline by 1, 2, and 3 kg in recipients of ziprasidone 20 mg, 40 mg, and 80 mg twice daily, respectively.
Ziprasidone had a negligible effect on body weight in two short-term studies.
Hyperglycemia has been reported in patients treated with atypical antipsychotics. In some cases, the hyperglycemia has been extreme and associated with ketoacidosis or hyperosmolar coma and death. There have been a few reports of hyperglycemia and diabetes in patients treated with ziprasidone.
Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Epidemiological studies (which did not include ziprasidone) suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics included in the studies.
Metabolic side effects have frequently included weight gain (10%). Increased transaminase, increased creatinine phosphokinase, increased alkaline phosphatase, increased lactic dehydrogenase, albuminuria, hypokalemia have also been reported. Increased BUN, increased creatinine, hyperlipemia, hypocholesteremia, hyperkalemia, hypochloremia, hyponatremia, hypoproteinemia, gout, hyperchloremia, hyperuricemia, hypocalcemia, hypomagnesemia, and respiratory alkalosis.
Oncologic side effects have been reported in animal studies. These animal studies have revealed dose-related increases in the incidence of pituitary gland adenoma and carcinoma, and gland adenocarcinoma.
A 32-year-old male with a history of schizophrenia reported unwanted penile erections lasting a duration of approximately 1 hour. The patient reported this effect starting approximately 10 weeks after initiation of ziprasidone (the active ingredient contained in Geodon) therapy and occurring at a rate of approximately 3 episodes per week. The patient mentioned this adverse effect to his clinician at a regular office visit approximately 1-month later. The problem resolved without recurrence following discontinuation of ziprasidone therapy.
Genitourinary side effects have included impotence, abnormal ejaculation, amenorrhea, hematuria, menorrhagia, female lactation, polyuria, urinary retention, metrorrhagia, male sexual dysfunction, anorgasmia, dysmenorrhea, and glycosuria. Gynecomastia, vaginal hemorrhage, nocturia, oliguria, female sexual dysfunction, and uterine hemorrhage have been reported rarely. Enuresis, urinary incontinence, and priapism have also been reported.
Hematologic side effects have infrequently included anemia, ecchymosis, leukocytosis, leukopenia, eosinophilia, and lymphadenopathy. Thrombocytopenia, hypochromic anemia, lymphocytosis, monocytosis, basophilia, lymphedema, polycythemia, thrombocythemia, neutropenia, and agranulocytosis have been reported rarely.
Hepatic side effects have rarely included jaundice, increased gamma glutamyl transpeptidase, cholestatic jaundice, hepatitis, hepatomegaly, and fatty liver deposit.
Hypersensitivity side effects have rarely included allergic reactions (such as allergic dermatitis, angioedema, orofacial edema, and urticaria) and rash.
Other side effects have frequently included accidental injury (4%), flu syndrome, fever, accidental fall, face edema, chills, photosensitivity reaction, flank pain, hypothermia, peripheral edema, thirst, dehydration, tinnitus, and motor vehicle accident.
Psychiatric side effects reported in the short-term trials with intramuscular ziprasidone (the active ingredient contained in Geodon) have included personality disorder and psychosis. Mania/hypomania and depression have also been reported rarely.
Local side effects associated with intramuscular ziprasidone (the active ingredient contained in Geodon) have frequently included pain at the injection site.
More about Geodon (ziprasidone)
Compare with other treatments for:
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.